BACKGROUND The burden of dyslipidaemia is rising in many low income countries. However, there are few data on the prevalence of, or risk factors for, dyslipidaemia in Africa. METHODS In 2011, we used the WHO Stepwise approach to collect cardiovascular risk data within a general population cohort in rural south-western Uganda. Dyslipidaemia was defined by high total cholesterol (TC) ≥ 5.2 mmol...

Mike Kirby is Visiting Professor, Centre for Research in Primary & Community Care, University of Hertfordshire. People with diabetes have an increased risk of cardiovascular complications, including acute coronary syndrome, stroke, heart failure and arrhythmias. The background to this risk for the development of cardiovascular complications is multifactorial and our understanding of the nature ...

Ezetimibe is a selective cholesterol absorption inhibitor with an excellent side-effect profile, able to reduce low-density lipoprotein (LDL) cholesterol by 15-25% from baseline in monotherapy and on top of statins and fibrates. Yet, it seems that ezetimibe produces quantitative rather than qualitative changes in LDL, with small net effects on atherogenic dyslipidaemia. This is supported by fin...

BACKGROUND Hypercholesterolaemia is a major risk factor for coronary heart disease (CHD) especially in industrialized societies. Coronary heart disease is becoming an increasing cause of death even in the developing world. OBJECTIVE To determine the prevalence of dyslipidaemia in apparently healthy professionals in a developing economy. METHOD One hundred apparently healthy professionals we...

OBJECTIVES To describe the fasting serum lipid and glucose profiles of HIV-positive Nigerian children and determine the prevalence and risk factors for dyslipidaemia and hyperglycaemia, which are risk factors for cardiovascular diseases. METHODS This was a comparative cross-sectional study carried out at the Paediatric Infectious Disease Clinic (PIDC) of the Jos University Teaching Hospital (...

Others have analysed the relationship between inadequate behaviour by healthcare professionals in the diagnosis of dyslipidaemia (diagnostic inertia) and the history of cardiovascular risk factors. However, since no study has assessed cardiovascular risk scores as associated factors, we carried out a study to quantify diagnostic inertia in dyslipidaemia and to determine if cardiovascular risk s...

INTRODUCTION Cardiovascular disease (CVD) is the leading cause of death globally and disproportionately affects low-income and middle-income countries. Dyslipidaemia is an important modifiable risk factor for CVD. There are important knowledge gaps regarding the population levels of lipid variables and frequency of non-optimal levels in populations within Africa. We propose to conduct a systema...

OBJECTIVE To assess the association between dietary energy density and the prevalence of cardiometabolic risk factors among Iranian adult women. DESIGN Cross-sectional study. SETTING Tehran, Islamic Republic of Iran. SUBJECTS We assessed habitual dietary intakes of 486 Iranian adult women by the use of a validated FFQ. Dietary energy density (DED) was calculated as each individual's repor...

Background: This study investigated the effects of age, gender, socio-economic status, smoking hypertension, ischaemic heart disease, Body Mass Index (BMI), Glycaemic control (HbA1c) and dyslipidaemia in type 2 diabetes a population-based analysis.

INTRODUCTION The incidence of dyslipidaemia is high: in 2000, approximately 25% of adults in the USA had total cholesterol greater than 6.2 mmol/L or were taking lipid-lowering medication. Primary prevention in this context is defined as long-term management of people at increased risk but with no clinically overt evidence of CVD - such as acute MI, angina, stroke, and PVD - and who have not un...